Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACHN NASDAQ:APRE NASDAQ:KNSA NASDAQ:RYTM NASDAQ:STOK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACHNAchillion Pharmaceuticals$6.76$6.76$2.06▼$7.01$946.72M1.598.44 million shsN/AAPREAprea Therapeutics$1.77-5.9%$1.74$1.41▼$5.01$9.79M1.1926,754 shs51,533 shsKNSAKiniksa Pharmaceuticals International$28.95+0.5%$27.69$17.82▼$30.69$2.11B0.05556,827 shs356,649 shsRYTMRhythm Pharmaceuticals$89.04+0.0%$63.88$40.61▼$94.58$5.66B2.26586,587 shs2.54 million shsSTOKStoke Therapeutics$12.04+0.2%$10.57$5.35▼$16.15$657.38M1.14674,463 shs596,598 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACHNAchillion Pharmaceuticals0.00%0.00%0.00%0.00%+754.41%APREAprea Therapeutics+4.44%+10.59%+2.17%+20.44%-50.00%KNSAKiniksa Pharmaceuticals International+5.84%+4.96%-5.04%+54.42%+42.36%RYTMRhythm Pharmaceuticals+36.63%+32.99%+33.39%+53.90%+98.04%STOKStoke Therapeutics+0.08%+4.07%+8.00%+84.36%-10.16%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACHNAchillion PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAPREAprea Therapeutics2.5092 of 5 stars3.54.00.00.00.00.81.3KNSAKiniksa Pharmaceuticals International3.4963 of 5 stars3.54.00.00.02.23.30.6RYTMRhythm Pharmaceuticals3.5144 of 5 stars2.52.00.04.32.60.80.6STOKStoke Therapeutics3.9066 of 5 stars3.60.00.04.81.70.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACHNAchillion Pharmaceuticals 0.00N/AN/AN/AAPREAprea Therapeutics 3.00Buy$15.50775.71% UpsideKNSAKiniksa Pharmaceuticals International 3.00Buy$39.3335.87% UpsideRYTMRhythm Pharmaceuticals 3.07Buy$89.360.36% UpsideSTOKStoke Therapeutics 3.29Buy$23.2092.69% UpsideCurrent Analyst Ratings BreakdownLatest RYTM, APRE, KNSA, ACHN, and STOK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025RYTMRhythm PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy7/10/2025RYTMRhythm PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$76.00 ➝ $110.007/10/2025RYTMRhythm PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$73.00 ➝ $95.007/10/2025RYTMRhythm PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$91.00 ➝ $129.007/10/2025RYTMRhythm PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$97.007/9/2025KNSAKiniksa Pharmaceuticals InternationalWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$30.00 ➝ $42.007/9/2025RYTMRhythm PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$72.00 ➝ $95.007/7/2025RYTMRhythm PharmaceuticalsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/7/2025RYTMRhythm PharmaceuticalsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform ➝ Outperform$88.007/1/2025STOKStoke TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.006/26/2025APREAprea TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$11.00(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACHNAchillion PharmaceuticalsN/AN/AN/AN/A$1.92 per shareN/AAPREAprea TherapeuticsN/AN/AN/AN/A$3.55 per shareN/AKNSAKiniksa Pharmaceuticals International$481.17M4.39N/AN/A$6.60 per share4.39RYTMRhythm Pharmaceuticals$130.13M43.53N/AN/A$0.35 per share254.40STOKStoke Therapeutics$36.56M17.98N/AN/A$4.32 per share2.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACHNAchillion Pharmaceuticals-$70.27M-$0.51N/AN/AN/AN/A-30.95%-29.09%N/AAPREAprea Therapeutics-$12.96M-$2.37N/AN/AN/A-1,095.02%-68.39%-55.74%8/11/2025 (Estimated)KNSAKiniksa Pharmaceuticals International-$43.19M-$0.25N/A115.80N/A-3.52%-3.83%-2.98%7/22/2025 (Estimated)RYTMRhythm Pharmaceuticals-$260.60M-$2.81N/AN/AN/A-123.26%-739.62%-44.27%8/5/2025 (Estimated)STOKStoke Therapeutics-$88.98M$0.7915.24N/AN/A26.33%19.08%15.72%8/5/2025 (Estimated)Latest RYTM, APRE, KNSA, ACHN, and STOK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025RYTMRhythm Pharmaceuticals-$0.64N/AN/AN/A$43.72 millionN/A8/5/2025Q2 2025STOKStoke Therapeutics-$0.0905N/AN/AN/A$31.51 millionN/A7/22/2025Q2 2025KNSAKiniksa Pharmaceuticals International$0.08N/AN/AN/AN/AN/A5/14/2025Q1 2025APREAprea Therapeutics-$0.6543-$0.66-$0.0057-$0.66N/A$0.16 million5/7/2025Q1 2025RYTMRhythm Pharmaceuticals-$0.69-$0.81-$0.12-$0.81$40.43 million$37.72 million4/29/2025Q1 2025KNSAKiniksa Pharmaceuticals International$0.02$0.11+$0.09$0.11$128.35 million$137.79 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACHNAchillion PharmaceuticalsN/AN/AN/AN/AN/AAPREAprea TherapeuticsN/AN/AN/AN/AN/AKNSAKiniksa Pharmaceuticals InternationalN/AN/AN/AN/AN/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/ASTOKStoke TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACHNAchillion Pharmaceuticals0.018.968.96APREAprea TherapeuticsN/A5.905.90KNSAKiniksa Pharmaceuticals InternationalN/A3.663.43RYTMRhythm PharmaceuticalsN/A3.303.13STOKStoke TherapeuticsN/A8.418.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACHNAchillion Pharmaceuticals79.42%APREAprea Therapeutics34.19%KNSAKiniksa Pharmaceuticals International53.95%RYTMRhythm PharmaceuticalsN/ASTOKStoke TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipACHNAchillion Pharmaceuticals4.58%APREAprea Therapeutics13.63%KNSAKiniksa Pharmaceuticals International53.48%RYTMRhythm Pharmaceuticals6.10%STOKStoke Therapeutics9.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACHNAchillion Pharmaceuticals56140.05 millionN/AOptionableAPREAprea Therapeutics75.53 million4.78 millionNo DataKNSAKiniksa Pharmaceuticals International22072.97 million33.95 millionOptionableRYTMRhythm Pharmaceuticals14063.62 million59.74 millionOptionableSTOKStoke Therapeutics10054.60 million49.41 millionOptionableRYTM, APRE, KNSA, ACHN, and STOK HeadlinesRecent News About These CompaniesLille rival Aston Villa in race for Stoke’s Sol SidibéJuly 10 at 10:48 AM | sports.yahoo.comAston Villa want Stoke City midfielder Sol SidibeJuly 10 at 10:48 AM | sports.yahoo.comCouncil still against Stoke-on-Trent 'merger' as devolution decision gets nearerJuly 10 at 10:48 AM | msn.comStoke City vs Shrewsbury LIVE Score Updates: Match CanceledJuly 10 at 10:48 AM | vavel.comVLive updates after 'accident' on Stoke-on-Trent roadJuly 10 at 10:48 AM | stokesentinel.co.ukSStoke City close in on fourth summer signingJuly 10 at 10:48 AM | msn.comStoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) CongressJuly 10 at 7:00 AM | businesswire.comBiogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) CongressJuly 10 at 7:00 AM | globenewswire.comLive updates as firefighters on scene of Stoke-on-Trent blazeJuly 8 at 6:12 PM | stokesentinel.co.ukSPolice helicopter tracks 4 masked kids on stolen motorbikes in Stoke-on-Trent parkJuly 8 at 6:12 PM | msn.comStoke-on-Trent firm collapses into administrationJuly 8 at 6:12 PM | msn.comDriver dies in Royal Stoke after hitting treeJuly 8 at 6:12 PM | msn.comStoke City move early for 'lethal' rising Manchester City star in second signing of the dayJuly 7 at 4:49 AM | msn.comNew Hanford waste incinerator could keep patients warm at Royal StokeJuly 7 at 4:49 AM | msn.comStoke sign Talovierov and Man City's MubamaJuly 7 at 4:49 AM | msn.comZebra crossings to be installed outside TWO schools on same Stoke-on-Trent roadJuly 5, 2025 | msn.comStoke-on-Trent-based Prohire Limited falls into administrationJuly 5, 2025 | bbc.co.ukMaksym Talovierov makes 'cold nights' promise with brilliant Stoke City statementJuly 5, 2025 | msn.comDONE DEAL: Stoke snap up Man City striker MubamaJuly 5, 2025 | tribalfootball.comTFive Guys to open first Stoke-on-Trent restaurantJuly 5, 2025 | msn.comStoke Therapeutics' (STOK) "Buy" Rating Reaffirmed at Needham & Company LLCJuly 1, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRYTM, APRE, KNSA, ACHN, and STOK Company DescriptionsAchillion Pharmaceuticals NASDAQ:ACHNAchillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trials; and ACH-5548, a factor D inhibitor, which is in Phase I clinical trials for the treatment of PNH and other complement mediated diseases. It has license agreements with Ora, Inc. for the development and commercialization of ACH-702; and GCA Therapeutics, Ltd for elvucitabine, a nucleoside reverse transcriptase inhibitor for the treatment of hepatitis B infection and human immunodeficiency virus infection. The company was founded in 1998 and is based in New Haven, Connecticut.Aprea Therapeutics NASDAQ:APRE$1.80 -0.08 (-4.26%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.Kiniksa Pharmaceuticals International NASDAQ:KNSA$28.95 +0.15 (+0.52%) Closing price 04:00 PM EasternExtended Trading$29.06 +0.11 (+0.36%) As of 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.Rhythm Pharmaceuticals NASDAQ:RYTM$89.04 +0.04 (+0.04%) Closing price 04:00 PM EasternExtended Trading$88.40 -0.65 (-0.72%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Stoke Therapeutics NASDAQ:STOK$12.04 +0.02 (+0.17%) Closing price 04:00 PM EasternExtended Trading$12.12 +0.08 (+0.62%) As of 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain BigBear.ai: Why a 90% Rally Could Be Just the Start Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Alphabet: Technical Momentum Is Starting to Turn Boeing's Rebound Is Well Underway—But Is It Too Late? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
